Antiphospholipid Antibody Syndrome and Recurrent Pregnancy Loss
Author Information
Author(s): Mercier Marion, Lescoat Alain, Pierre-Jean Morgane, Dumontet Erwan, Le Lous Maela, Belhomme Nicolas
Primary Institution: University Hospital of Rennes
Hypothesis
What is the impact of the 2023 ACR/EULAR classification criteria for antiphospholipid syndrome on the prevalence of rheumatic diseases among patients with recurrent pregnancy loss?
Conclusion
The study found that the prevalence of antiphospholipid syndrome decreased significantly from 14% to 1.2% when applying the updated criteria.
Supporting Evidence
- APS was diagnosed in 14% of patients using the Sydney criteria but only in 1.2% with the updated criteria.
- The overall prevalence of autoimmune diseases in the study population was 17%.
- Only three patients were newly diagnosed with rheumatic diseases other than APS during the study.
Takeaway
This study looked at women who had multiple miscarriages and found that very few had a specific syndrome that could explain their losses, especially when using new guidelines.
Methodology
A retrospective cohort study was conducted at Rennes University Hospital, including patients referred for recurrent pregnancy loss from January 2010 to December 2021.
Potential Biases
Potential selection bias due to the study being conducted at a single tertiary care center.
Limitations
The study was limited by its sample size and conducted at a single center, which may introduce selection bias.
Participant Demographics
The study included 165 women with recurrent pregnancy loss, primarily Caucasian, with a median age of 33.3 years.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website